Table 3. Multivariable Regression Analysis for Prognostication of Type 2 Myocardial Infarction (T2MI).
| Test | Patients, No. | Model 1a | Model 2b | |||
|---|---|---|---|---|---|---|
| With T2MI | With T1MI | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
| Cardiomyocyte injury | ||||||
| High-sensitivity cardiac troponin T | ||||||
| 0 h | 246 | 851 | 0.23 (0.16-0.33) | <.001 | 0.31 (0.15-0.64) | .001 |
| 1 h | 215 | 680 | 0.15 (0.10-0.23) | <.001 | 0.30 (0.13-0.67) | .003 |
| 2 h | 164 | 531 | 0.14 (0.09-0.24) | <.001 | 0.31 (0.13-0.76) | .01 |
| High-sensitivity cardiac troponin I | ||||||
| 0 h | 241 | 848 | 0.37 (0.29-0.45) | <.001 | 0.43 (0.28-0.66) | <.001 |
| 1 h | 206 | 662 | 0.32 (0.25-0.41) | <.001 | 0.46 (0.29-0.73) | .001 |
| 2 h | 160 | 510 | 0.31 (0.23-0.41) | <.001 | 0.50 (0.30-0.84) | .008 |
| Creatine kinase–myocardial band | 81 | 377 | 0.24 (0.13-0.47) | <.001 | 0.10 (0.02-0.57) | .009 |
| Heart-type fatty acid–binding protein | 55 | 165 | 0.45 (0.22-0.91) | .03 | NA | NA |
| Cardiac myosin-binding protein C | ||||||
| 0 h | 105 | 303 | 0.33 (0.22-0.49) | <.001 | 0.32 (0.13-0.75) | .009 |
| 1 h | 93 | 246 | 0.27 (0.18-0.43) | <.001 | 0.44 (0.19-1.06) | .07 |
| 2 h | 68 | 196 | 0.25 (0.15-0.42) | <.001 | NA | NA |
| Hemodynamic cardiac stress | ||||||
| B-type natriuretic peptide | 115 | 402 | 1.52 (0.70-3.28) | .29 | 1.23 (0.16-9.20) | .84 |
| N-terminal pro B-type natriuretic peptide | 50 | 140 | 0.97 (0.55-1.71) | .91 | NA | NA |
| Midregional pro–A-type natriuretic peptide | 37 | 97 | 12.12 (2.13-69.92) | .005 | NA | NA |
| Endogenous stress | ||||||
| Copeptin | ||||||
| 0 h | 104 | 306 | 0.90 (0.56-1.43) | .64 | 1.55 (0.60-3.96) | .36 |
| 1 h | 87 | 231 | 0.74 (0.43-1.28) | .29 | 1.18 (0.37-3.79) | .78 |
| 2 h | 64 | 174 | 1.21 (0.62-2.39) | .58 | NA | NA |
| Glucose | 241 | 832 | 1.05 (0.75-1.45) | .79 | 0.68 (0.33-1.39) | .28 |
| Plaque instability and angiogenesis | ||||||
| Myeloperoxidase | 36 | 94 | 1.54 (0.67-3.50) | .31 | NA | NA |
| Soluble vascular endothelial growth factor receptor | 36 | 96 | 1.00 (0.50-1.99) | .99 | NA | NA |
| Placental growth factor | 24 | 65 | 4.06 (0.07-227.75) | .50 | NA | NA |
| Pregnancy-associated plasma protein-A | 24 | 65 | 0.78 (0.18-3.37) | .74 | NA | NA |
| Autoantibodies to apolipoprotein A-1 IgG OD | 55 | 163 | 0.76 (0.31-1.83) | .54 | NA | NA |
| Antiphosphorylcholine IgM | 55 | 163 | 0.46 (0.16-1.31) | .15 | NA | NA |
| Endothelial dysfunction | ||||||
| C-terminal proendothelin 1 | 37 | 97 | 31.06 (2.08-464.61) | .01 | NA | NA |
| Midregional proadrenomedullin | 103 | 305 | 10.79 (2.45-47.47) | .002 | 35.19 (2.24-553.26) | .01 |
| Inflammation | ||||||
| C-reactive protein | 204 | 669 | 1.13 (0.87-1.47) | .35 | 1.15 (0.93-2.33) | .10 |
| Leukocytes | 245 | 850 | 0.96 (0.37-2.51) | .93 | 2.70 (0.51-14.35) | .25 |
| Combination of inflammation, hemodynamic stress, and vascular aging | ||||||
| Growth differentiation factor 15 | 37 | 91 | 4.76 (0.73-31.13) | .10 | NA | NA |
Abbreviations: NA, not applicable; T2MI, type 2 myocardial infarction.
a
Model 1 was adjusted for sex, creatinine clearance, and previous myocardial infarction.
b
Model 2 was adjusted for sex, creatinine clearance, previous myocardial infarction, age, heart rate, systolic blood pressure, hypercholesterolemia, and body mass index.